Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Director Paul B. Manning acquired 70,200 shares of the company’s stock in a transaction that occurred on Tuesday, November 13th. The shares were bought at an average price of $14.15 per share, for a total transaction of $993,330.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of NASDAQ:VRCA traded down $1.66 during midday trading on Wednesday, reaching $13.57. 120,000 shares of the company were exchanged, compared to its average volume of 61,892. Verrica Pharmaceuticals Inc has a fifty-two week low of $11.41 and a fifty-two week high of $23.29.
Verrica Pharmaceuticals (NASDAQ:VRCA) last released its earnings results on Wednesday, November 7th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). Research analysts predict that Verrica Pharmaceuticals Inc will post -1.17 earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in VRCA. Bank of New York Mellon Corp bought a new position in Verrica Pharmaceuticals in the third quarter valued at $195,000. Capital Investment Advisory Services LLC bought a new position in Verrica Pharmaceuticals in the second quarter valued at $211,000. Laurion Capital Management LP bought a new position in Verrica Pharmaceuticals in the second quarter valued at $395,000. Dean Capital Investments Management LLC bought a new position in Verrica Pharmaceuticals in the second quarter valued at $676,000. Finally, Asymmetry Capital Management L.P. bought a new position in Verrica Pharmaceuticals in the second quarter valued at $1,184,000. 31.94% of the stock is owned by institutional investors and hedge funds.
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.
Recommended Story: How can investors find ex-dividend dates?
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.